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Abstract
The majority of patients recur after resection of colorectal liver metastases (CRLM). Patients with CRLM displaying a des-
moplastic histopathological growth pattern (dHGP) have a better prognosis and lower probability of recurrence than patients 
with non-dHGP CRLM. The current study evaluates the impact of HGP type on the pattern and treatment of recurrences after 
first resection of CRLM. A retrospective cohort study was performed, including patients with known HGP type after complete 
resection of CRLM. All patients were treated between 2000 and 2015. The HGP was determined on the CRLM resected at 
first partial hepatectomy. The prognostic value of HGPs, in terms of survival outcome, in the current patient cohort were 
previously published. In total 690 patients were included, of which 492 (71%) developed recurrent disease. CRLM displaying 
dHGP were observed in 103 patients (21%). Amongst patients with dHGP CRLM diagnosed with recurrent disease, more 
liver-limited recurrences were seen (43% vs. 31%, p = 0.030), whereas patients with non-dHGP more often recurred at mul-
tiple locations (34% vs. 19%, p = 0.005). Patients with dHGP CRLM were more likely to undergo curatively intended local 
treatment for recurrent disease (adjusted odds ratio: 2.37; 95% confidence interval (CI) [1.46–3.84]; p < 0.001) compared 
to patients with non-dHGP. The present study demonstrates that liver-limited disease recurrence after complete resection of 
CRLM is more often seen in patients with dHGP, whereas patients with non-dHGP more frequently experience multi-organ 
recurrence. Recurrences in patients with dHGP at first CRLM resection are more likely to be salvageable by local treatment 
modalities, but no prognostic impact of HGPs after salvage therapy for recurrent disease was found.
Keywords Colorectal liver metastases · Histopathological growth patterns · Salvageable recurrences · Biomarker · 
Prognostication
Introduction
After hepatic resection for colorectal liver metastases 
(CRLM) the majority of patients experiences recurrence of 
disease. Despite advances in the treatment of CRLM, recur-
rence rates reach up to 70% [1–5]. Approximately 40% of 
the patients with recurrent disease is again eligible for local 
treatment modalities [4, 6–8]. If disease biology allows the 
recurrence to be treated locally again, survival outcomes 
similar to the first local treatment of metastases are seen 
[1, 4, 6–13]. In case of a recurrence not amenable to local 
treatment prognosis is limited [4, 7, 8, 13]. In addition, clini-
cal risk factors currently used for the prediction of progno-
sis after first hepatic resection for CRLM, have not proven 
equally useful in prognostication after repeat resection for 
recurrent CLRM [14].
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Histopathological growth patterns (HGPs) describe the 
transition border of CRLM to the normal liver parenchyma 
[15]. The assessment of HGPs has been standardised in 
international consensus guidelines [16] and multiple stud-
ies have reported the effect of HGPs on prognosis in patients 
with resectable CRLM [16–22]. We recently described the 
largest patient cohort to date and found that the desmoplastic 
HGP (dHGP) is associated with favourable overall survival, 
progression free survival compared to its non-desmoplastic 
counterpart (non-dHGP) [23]. In the current study we aimed 
to identify in the same cohort of patients potential explana-
tions for this survival difference. Differences in recurrence 
pattern (intra- versus extrahepatic) and/or treatment of recur-
rent disease (local vs. systemic) might possibly account for 
the difference in survival outcomes between HGPs. There-
fore, the current study investigates the pattern of first recur-
rence and the salvageability of recurrent disease after first 
partial hepatectomy for CRLM in the context of HGPs.
Methods
Patients
The current study was approved by the medical ethics com-
mittee of the Erasmus University Medical Centre Rotterdam 
(MEC 2018-1743). All consecutive patients that underwent 
first surgical treatment for CRLM between 2000 and 2015 at 
the Erasmus MC Cancer Institute were considered for inclu-
sion. The prognostic value of HGPs, in terms of survival 
outcome, in the current patient cohort were previously pub-
lished [23]. Patients selected for this study had to be com-
pletely free of all known macroscopic disease at some point 
following first resection of CRLM in order to be eligible for 
inclusion. A positive resection margin (R1) was defined as 
tumour cells (i.e. microscopic residual disease) at the resec-
tion margin and therefore patients with an R1 resection were 
eligible for inclusion. Patients with unknown HGP type were 
excluded.
Design and outcomes
Data on patient characteristics, primary tumour, CRLM and 
recurrence were extracted from a prospectively maintained 
database. H&E tissue sections were retrospectively ana-
lysed for HGP assessment. Disease free survival (DFS) was 
defined as the time in months between the first hepatic resec-
tion for CRLM and diagnosis of recurrence or death. Post-
recurrence survival (PRS) was defined as the time in months 
between diagnosis of recurrence after first hepatic resection 
for CRLM and death. When alive patients were censored 
at date of last follow-up. Local therapy with curative intent 
was defined as resection, ablation and/or radiation therapy 
after which the patient was considered to be free of disease.
Treatment and follow‑up after first partial 
hepatectomy
Perioperative chemotherapy for resectable CRLM is not 
standard of care in the Netherlands, since no OS benefit has 
been found in randomised setting [24]. Therefore preopera-
tive chemotherapy at the Erasmus MC Cancer Institute is 
only considered in case of borderline resectable, more than 
four and/or synchronous CRLM. Some patients, however, 
received chemotherapy in referring hospitals prior to refer-
ral. Patients do not receive postoperative chemotherapy. Fol-
low-up is performed up to 5 years after resection of CLRM. 
The follow-up consists of carcinoembryonic antigen (CEA) 
monitoring every 3 months for the entire follow-up duration 
and imaging every 6 months in the first 3 years and annually 
in the fourth and fifth year. In case of elevated CEA levels 
(> 5 µg/L) or a rise in CEA levels (> 25%) imaging is per-
formed. When uncertainty with regard to the diagnosis of 
disease recurrence exists, biopsies are taken as confirmation. 
As with primary treatment for CRLM, treatment strategy 
for recurrent disease is established by a multidisciplinary 
board. The decision whether local therapies (resection, abla-
tion, stereotactic body radiation) are considered beneficial 
for patients, depends on two factors: time to recurrence and 
localisation of recurrences.
Regarding time to recurrence, it was previously demon-
strated that patients with a disease-free interval of less than 
6 months again undergoing local treatment for the recurrence 
have poor survival outcomes [25]. Therefore, when patients 
present with recurrent disease within 6 months after resec-
tion of CRLM, patients first receive systemic chemotherapy 
before local therapy is considered. Systemic therapy nor-
mally consists of oxaliplatin- or irinotecan-based treatment 
regimens. Typically, three courses are administered followed 
by restaging and local therapy in case of partial response or 
stable disease. In case of progressive disease, patients are 
switched to second line chemotherapeutic regimens. When 
patients present with recurrent disease beyond 6 months 
after primary liver resection for CRLM and the lesions are 
treatable with local therapy, these patients are planned for 
local therapy accordingly. Again, no adjuvant chemotherapy 
is administered. Patients presenting with recurrent disease 
not eligible for local treatment receive palliative treatment.
Provided that the interval between first liver resection and 
recurrence is greater than 6 months, or less than 6 months, 
but at least stable disease after three courses of chemother-
apy is observed, then localisation of recurrences is a deci-
sive factor in the clinical decision making in these patients. 
The currently handled standard at our centre is, that when 
recurrent disease is liver-limited and it can be resected with 
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sufficient remnant liver, local treatment of the colorectal 
liver metastases should be attempted. In addition, local treat-
ment is deemed feasible when concurrent oligometastatic 
extrahepatic is present. When extrahepatic disease is present 
in > 1 organ, local treatment is deemed futile.
HGP assessment
The HGPs were determined on the CRLM resected at 
the first hepatectomy. The HGP of CRLM describes the 
tumour-liver interface. Three different types of HGPs have 
been described; the desmoplastic (dHGP), the replacement 
(rHGP) and the rare pushing HGP (pHGP) [16]. The latter 
two (rHGP and pHGP) can be taken together as non-dHGP, 
since recent findings indicate that patients with CRLM that 
display any proportion non-dHGP at the interface have 
impaired prognosis compared to patients with pure dHGP 
[23]. In this study, international consensus guidelines 
for HGP assessment of liver metastases were utilised to 
determine the HGPs [16]. HGP determination was jointly 
executed by at least three trained observers (PN, BG, DH, 
ES, RC, PV). The observers were blinded for clinical data 
and outcome during HGP assessment. Some CRLM dis-
play multiple HGPs, therefore the complete interface of all 
available H&E tissue sections of all CRLM in every patient 
were examined. Only if pure dHGP was observed, patients 
were categorised as such. All other patient displaying any 
non-dHGP were categorised as non-dHGP. In accordance 
with the consensus guidelines, not all tissue sections are 
suitable for HGP assessment. If less than 20% of the inter-
face is assessable, if the tissue section is of insufficient qual-
ity or when no vital tumour is present, the HGP cannot be 
determined.
Statistical analysis
Categorical data were presented using counts and percent-
ages. Continuous data were reported with medians and cor-
responding interquartile range (IQR). Differences in pro-
portions were evaluated with the Chi-squared test. Medians 
were compared using the Mann–Whitney U test. Median 
follow-up time for survivors was estimated by means of the 
reversed Kaplan–Meier method. Survival estimates were 
obtained using the Kaplan–Meier method, computed until 
60 months and compared with the log rank test. Uni- and 
multivariable Cox regression analysis was performed to cor-
rect for potential confounding. Results of the Cox regression 
analyses were expressed in hazard ratios (HR) and corre-
sponding 95% confidence intervals (CI). Uni- and multivari-
able binary logistic regression analysis was performed to 
evaluate possible predictors for unsalvageable recurrence. 
Results of the logistic regression analyses were expressed 
in odds ratios (OR) and corresponding 95% CI. In both the 
binary logistic regression and the Cox univariable regres-
sion models, all variables potentially related to salvageabil-
ity of recurrence and/or overall survival were considered. All 
variables with p-values < 0.100 on univariable analysis were 
entered in the multivariable models. All statistical tests were 
two-sided and p-values < 0.05 were considered statistically 
significant. All analyses were performed using SPSS version 
24.0 (SPSS Inc., Chicago, IL) and R version 3.5.1 (http://
www.r-proje ct.org).
Results
Patients and disease free survival
During the study period 964 patients were treated surgi-
cally for CRLM at the Erasmus MC Cancer Institute. HGP 
determination was performed in 732 patients (76%). Patients 
were excluded due to: no (complete) resection of CRLM 
(n = 100), missing H&E tissue sections (n = 55), ablative 
therapy only (n = 21) or non-suitable H&E tissue sections for 
HGP determination (n = 56). Of these 732 patients, 690 were 
completely free of all known disease at some point follow-
ing first resection of CRLM and were included in the study. 
Hence, 42 patients were excluded (n = 24 primary tumour 
never resected after liver-first approach due to progressive 
metastatic disease, n = 18 extrahepatic disease never treated 
locally).
Among the included patients, there were 173 (25%) with 
dHGP and 517 with non-dHGP (75%). Median follow-up 
for survivors was 76 months (IQR: 45–116). In total 492 
patients (71%) had disease recurrence. A flowchart of the 
patient inclusion is displayed in Fig. 1. Baseline character-
istics of all 690 patients compared for HGP are reported in 
Table 1. At baseline there were several differences between 
patients with dHGP compared to patients non-dHGP, espe-
cially in terms of primary tumour characteristics (lymph 
node status and adjuvant treatment) and CRLM character-
istics (disease-free interval, CEA, size of largest CRLM, 
resection margin and preoperative treatment).
Recurrence: survival, pattern and treatment
A smaller proportion of patients with dHGP had disease 
recurrence compared to patients with non-dHGP (60% vs. 
75%). Median DFS of patients with dHGP was 17 months 
(IQR: 7-not reached) compared to 10 months (IQR: 5–28) 
in patients with non-dHGP. The DFS significantly differed 
between both groups (p < 0.001, Fig. 2).
In total 492 patients had disease recurrence after first 
resection of CRLM. The median time to recurrence in 
these 492 patients with recurrent disease was 8 months 
(IQR: 5–14). This was 9 months (IQR: 6–14) in patients 
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with dHGP compared to 8 months (IQR: 4–13 months) in 
patients with non-dHGP. At 6 months after first liver resec-
tion, 57% of patients with non-dHGP developing recurrences 
was disease-free, while 71% of patients with dHGP tumours 
developing recurrences was disease-free at this point in time. 
Data on the pattern of first recurrence stratified for HGP 
are reported in Table 2. Patients with dHGP at first partial 
hepatectomy more often had an intrahepatic only recur-
rence (43% vs 31%, p = 0.030) whereas patients with non-
dHGP more often had a multi-organ (≥ 2) recurrence (34% 
vs 19%, p = 0.005). Of all 492 patients with a recurrence, 
224 (46%) were again treated with curative intent. Patients 
with dHGP were more often treated with curative intent for 
the recurrence (59% vs. 42%, p = 0.002). After correction 
for potential confounders, dHGP at first partial hepatectomy 
remained a significant predictor for salvageable recurrence 
(OR: 2.37, p < 0.001). Significant predictors negatively asso-
ciated with salvageability were a right-sided primary tumour 
(OR: 0.36, p < 0.001), a node positive primary tumour (OR: 
0.57, p = 0.008) and larger CRLM at first partial hepatec-
tomy (OR: 0.92, p = 0.036) (Table 3).
As the higher rate of intrahepatic only recurrences in the 
dHGP group might explain the higher likelihood of cura-
tively intended salvage treatment additional analyses have 
Fig. 1  Flowchart of patient selection
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Table 1  Baseline characteristics 
of all patients stratified for HGP Total N = 690 dHGP N = 173 Non-dHGP N = 517 p-value
Gender
 Male 445 (65%) 109 (63%) 336 (65%) 0.637
 Female 245 (36%) 64 (37%) 181 (35%)
Age
 Median (IQR) 65 (58–71) 65 (56–72) 64 (58–71) 0.984
ASA
 ASA I-II 617 (91%) 153 (89%) 464 (91%) 0.351
 ASA > II 63 (9%) 19 (11%) 44 (9%)
 Missing 10 patients
Primary tumour characteristics
 Location
  Right-sided 116 (17%) 30 (17%) 86 (17%) 0.927
  Left-sided 302 (44%) 76 (44%) 226 (44%)
  Rectum 256 (37%) 62 (36%) 194 (38%)
  Double tumour 16 (2%) 5 (3%) 11 (2%)
pTumour stage
 pT0-2 134 (20%) 39 (23%) 95 (19%) 0.239
 pT3-4 546 (80%) 132 (77%) 414 (81%)
 Missing 10 patients
Nodal status
 N0 270 (40%) 79 (47%) 191 (38%) 0.035*
 N+ 407 (60%) 90 (53%) 317 (62%)
 Missing 13 patients
Adjuvant chemotherapy primary tumour
 No 587 (85%) 160 (93%) 427 (83%) 0.002*
 Yes 103 (15%) 13 (8%) 90 (17%)
CRLM characteristics
 Synchronous CRLM
  No 329 (48%) 264 (51%) 65 (38%) 0.002*
  Yes 361 (52%) 253 (49%) 108 (62%)
Disease-free interval (months)
 Median (IQR) 2 (0–17) 0 (0–13) 5 (0–18) 0.006*
Number of CRLM
 Median (IQR) 2 (1–4) 2 (1–4) 2 (1–4) 0.886
Size of largest CRLM (cm)
 Median (IQR) 3.1 (2.0-4.5) 2.5 (1.8–4.2) 3.3 (2.3–4.8) < 0.001*
 Missing 2 patients
Preoperative CEA (µg/L)
 Median (IQR) 14.0 (4.7–50.0) 7.6 (3.2–30.0) 16.2 (5.1–53.0) < 0.001*
 Missing 28 patients
Fong CRS
 Low 408 (61%) 101 (61%) 307 (61%) 0.924
 High 262 (39%) 64 (39%) 198 (39%)
 Incomplete CRS 20 patients
Bilobar metastases
 No 418 (61%) 106 (61%) 312 (60%) 0.830
 Yes 272 (39%) 67 (39%) 205 (40%)
Preoperative CTx
 No 365 (53%) 68 (39%) 297 (57%) < 0.001*
 Yes 325 (47%) 105 (61%) 220 (43%)
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been performed, specifically excluding patients with intra-
hepatic recurrences only. We subsequently conducted the 
same multivariable logistic regression analysis as conducted 
previously and, despite excluding patients with liver-limited 
recurrences, still found a statistically significant association 
between dHGP and salvage treatment of the recurrence 
(adjusted OR: 3.16, p < 0.001).
Post‑recurrence survival
Median PRS after diagnosis of recurrence was 28 months 
(IQR: 15–59 months). Patients treated with curative intent 
had a median PRS of 56 months (IQR: 27–84 months) com-
pared to 19 months (IQR: 11–32 months) for patients receiv-
ing palliative treatment (p < 0.001). After stratification for 
treatment intent, no difference in PRS was observed between 
patients with dHGP and non-dHGP (both p-values > 0.25, 
Fig. 3).
Discussion
The current study demonstrates that patients with dHGP at 
first CRLM resection more often develop an intrahepatic 
only recurrence, whereas patients with non-dHGP more 
often experience multi-organ recurrence. Importantly, dHGP 
at first CRLM resection is independently associated with 
salvageable recurrences after first partial hepatectomy for 
CRLM. Prognosis after salvage treatment for recurrent dis-
ease is not impacted by HGP type determined at first resec-
tion of CRLM.
Unfortunately, the majority of patients develops a recur-
rence after curatively intended resection of CRLM [1–12]. 
The prognosis of patients with recurrent disease strongly 
depends on whether local treatment can still be performed. 
Disease load and tumour biology largely determine if local 
therapy is possible and beneficial [4, 10, 12, 26]. As this 
study shows, that recurrences in patients with dHGP at 
first CRLM resection are more likely to be salvageable, 
this potentially explains the observed outcome difference 
between patients with dHGP and non-dHGP. Several stud-
ies have suggested that dHGP is associated with favourable 
tumour characteristics and a lower recurrence rate [16–23]. 
Table 1  (continued) Total N = 690 dHGP N = 173 Non-dHGP N = 517 p-value
Resection margin
 R0 585 (85%) 158 (92%) 427 (83%) 0.004*
 R1 102 (15%) 14 (8%) 88 (17%)
 Missing 3 patients
Extra hepatic disease
 No 629 (91%) 157 (91%) 472 (91%) 0.827
 Yes 61 (9%) 16 (9%) 45 (9%)
Major liver resection
 <3 complete segments 455 (66%) 122 (71%) 333 (64%) 0.142
 ≥3 complete segments 235 (34%) 51 (30%) 184 (36%)
Recurrence after first resection CRLM
 No 198 (29%) 70 (40%) 128 (25%) < 0.001*
 Yes 492 (71%) 103 (60%) 389 (75%)
*Indicates significant p-value
Percentages do not always add up to 100% due to rounding
ASA American Society of Anaesthesiologists, CEA carcinoembryonic antigen, CRLM colorectal liver 
metastases, CRS clinical risk score, CTx Chemotherapy, HGP histopathological growth pattern, IQR inter-
quartile range, R1 irradical resection margin
Fig. 2  DFS after first hepatic resection for CRLM compared for HGP
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The more favourable tumour behaviour of dHGP CRLM was 
further acknowledged in this study, as patients with dHGP 
at first CRLM resection more often experience intra-hepatic 
only recurrence, whereas patients with non-dHGP more 
often develop multi-organ metastases. This also partially 
explains why salvage therapy was more often performed in 
these patients, as repeat resection of isolated recurrences 
is often feasible [1, 4, 6, 7, 9–12]. There were several dif-
ferences observed at baseline between patients with dHGP 
compared to patients with non-dHGP in terms of clinical 
risk. Patients with non-dHGP had a greater proportion 
lymph node positive primaries, larger CRLM, and more 
often an R1 resection margin. These differences might also 
have attributed to the greater risk of multi-organ recurrences 
that are less likely salvageable with local treatment modali-
ties in patients with non-dHGP. However, after correction 
for potentially confounding factors, dHGP remained signifi-
cantly associated with salvageable recurrences. In addition, 
this study shows that patients with dHGP less often develop 
a recurrence and, if they do, the recurrence is also more 
often salvageable with local treatment modalities.
Table 2  Recurrence pattern
*Indicates significant p-value
Total (N = 492) dHGP (N = 103) Non-dHGP (N = 389) p-value
Intrahepatic only 166 (34%) 44 (43%) 122 (31%) 0.030*
Pulmonary only 104 (21%) 22 (21%) 82 (21%) 0.951
One other location only 70 (14%) 17 (17%) 53 (14%) 0.457
   Local recurrence primary only 15 (3%) 3 (3%) 12 (3%)
   Peritoneal only 3 (1%) 1 (1%) 2 (1%)
   Distant lymph nodes only 26 (5%) 7 (7%) 19 (5%)
   Other location only 26 (5%) 6 (6%) 20 (5%)
Two or more locations 152 (31%) 20 (19%) 132 (34%) 0.005*
   Intrahepatic and pulmonary only 49 (10%) 10 (10%) 39 (10%)
   Intrahepatic and 1 other only 41 (8%) 3 (3%) 38 (10%)
   Pulmonary and 1 other only 25 (5%) 1 (1%) 24 (6%)
   Peritoneal and 1 other only 2 (1%) 0 (0%) 2 (1%)
   Multi organ (> 2) 35 (7%) 6 (6%) 29 (8%)
Treatment of recurrence with curative intent 224 (46%) 61 (59%) 163 (42%) 0.002*
Table 3  Logistic regression for 
salvageable recurrence
*Indicates significant p-value
ASA American Society of Anaesthesiologists, CEA carcinoembryonic antigen, cont. continuous, CRLM 
colorectal liver metastases, R1 irradical resection margin
Variable Univariable Multivariable
Odds ratio [95% CI] P-value Odds ratio [95% CI] p-value
Age at resection CRLM (cont.) 0.986 [0.968–1.004] 0.122
ASA > II 0.879 [0.470–1.642] 0.685
Right-sided primary 0.416 [0.249–0.694] 0.001* 0.364 [0.211–0.628] < 0.001*
pT3-4 0.534 [0.334–0.855] 0.009* 0.686 [0.409–1.151] 0.153
Node positive primary 0.490 [0.336–0.715] < 0.001* 0.568 [0.375–0.860] 0.008*
Disease free interval (cont.) 1.011 [1.001–1.022] 0.037* 1.013 [1.003–1.024] 0.014*
Number of CRLM (cont.) 0.949 [0.880–1.023] 0.171
Diameter largest CRLM (cont.) 0.932 [0.862–1.007] 0.076 0.915 [0.842–0.994] 0.036*
Preoperative CEA level (cont.) 1.000 [0.999-1.000] 0.270
Preoperative chemotherapy 1.210 [0.849–1.727] 0.292
R1 resection CRLM 0.971 [0.607–1.554] 0.903
Extra hepatic disease 0.864 [0.483–1.545] 0.622
Desmoplastic type tumours 2.014 [1.295–3.132] 0.002* 2.370 [1.462–3.840] < 0.001*
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A frequently debated contraindication for local treatment 
of colorectal liver metastases is the simultaneous presence 
of extrahepatic disease. However, several recent (reviews 
of) retrospective series support resection of liver metastases 
and concurrent mono-organic extrahepatic disease in highly 
selected patients [27–30]. When extrahepatic disease is pre-
sent in > 1 organ, the benefit of local treatment seems ques-
tionable as it holds outcome similar to systemic treatment 
alone [30]. As we demonstrated that multi-organ metastasis 
are more often found in patients with non-dHGP, we believe 
that this also partially explains why salvage treatment is less 
often performed in these patients. Moreover, several stud-
ies have demonstrated that some localisations of (recurrent) 
metastases (e.g. liver and concurrent para-aortic lymph 
node metastases [31, 32]) are associated with poor survival 
outcomes after surgery. Therefore, local therapies are often 
not considered beneficial in these patients. The true value 
of maximal tumour debulking in metastatic colorectal can-
cer will only be known after the completion of the ongoing 
ORCHESTRA trial (NCT01792934) in which patients are 
randomised between chemotherapy alone or the combination 
of chemotherapy and maximal tumour debulking.
The differences in recurrence patterns between HGP 
types might have implications for perioperative treatment. 
As patients with non-dHGP at first CRLM resection more 
often develop multi-organ recurrence, one could hypothesize 
that perioperative chemotherapy is more effective in these 
patients, since patients at high risk of (systemic) recurrence 
appear to benefit more from perioperative systemic treat-
ment [33, 34]. Vice versa, patients with dHGP at first CRLM 
resection might benefit more from hepatic arterial infusion 
(HAI) chemotherapy as they are more likely to develop 
recurrences confined to the liver. This hypothesis is sup-
ported by the recent finding that patients with low clinical 
risk, and therefore are less likely to develop extrahepatic 
disease, appear to benefit the most from HAI chemotherapy 
whereas patients with extrahepatic disease do not seem to 
benefit from HAI chemotherapy [35]. Future studies should 
evaluate the effect of perioperative treatment in the context 
of HGPs.
As the scoring was performed jointly and the final HGP 
score was determined by consensus between all observers, 
no Kappa value for this specific study can be provided. How-
ever, in another recently submitted manuscript by our group 
we have found excellent Kappa indices (> 0.9) for discrimi-
nation between dHGP and non-dHGP [36].
This is the first paper demonstrating a significant associa-
tion between distinct HGPs and differences in recurrence 
pattern in patients treated surgically for CRLM. Eefsen and 
colleagues [18] reported on the recurrence pattern in the 
context of HGPs but did not find an association. Importantly, 
the authors in that study applied an arbitrary cut-off value for 
the determination of the pre-dominant HGP. Recent insights 
have shown that the presence of any non-dHGP entails poor 
prognosis and no cut-off value for determination of the 
predominant HGP should be applied [23]. In addition, the 
number of patients with a recurrence in their study was lim-
ited and therefore a potential lack of power should also be 
considered. The current study handled no arbitrary cut-off 
value for pre-dominant HGP determination and describes 
a sufficiently large cohort, in which proper correction for 
confounding could be performed.
Most of the currently available risk factors for worse 
outcome after first resection of CRLM do not hold similar 
prognostic value when utilised for preoperative prognosis 
prediction at repeat resection of recurrent CRLM [14]. This 
indicates that there is a need for new prognostic markers in 
patients undergoing repeat partial hepatectomies for recur-
rent CRLM. This is the first study to evaluate the prognostic 
impact of HGPs of the CRLM resected at first liver resection 
for prognosis after repeat resection of CRLM. No differ-
ence in PRS was observed between patients with dHGP and 
non-dHGP. The reason that the HGP of the CRLM resected 
at first liver resection, rather than the HGP of recurrent 
CRLM resected at repeat resection, were used in the cur-
rent study was twofold. Firstly, if the HGP at first resection 
had proven to be prognostic after repeat resection it would 
have become not only a predictive marker for prognosis after 
first resection, but also a pre-salvage treatment marker for 
local treatment of the recurrence. Secondly, this cohort also 
describes patients with an extrahepatic recurrence without 
Fig. 3  PRS compared for HGP and treatment intent of the recurrence. 
D-C dHGP and curative intent, ND-C Non-dHGP and curative intent, 
D-NC dHGP and non-curative intent, ND-NC Non-dHGP and non-
curative intent
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a concurrent hepatic recurrence and therefore no HGP of an 
recurrent CRLM could be utilised.
Recently RAS mutational status has also been associated 
with unsalvageable recurrences [4]. Unfortunately RAS 
and BRAF mutational status were unknown in the currently 
described patient cohort at time of resection. In an attempt 
to correct for this drawback, primary tumour location (right- 
vs. left-sided) was taken into account in the multivariable 
analysis. Right-sided tumours have been associated with the 
presence of KRAS [37, 38] and BRAF [37–40] mutations. 
Right-sidedness of the primary tumour was independently 
negatively associated with salvageability of recurrent disease 
in the present study. Despite correcting for primary tumour 
location (and thereby partially correcting for mutational sta-
tus) HGP type remained statistically associated with salvage-
ability of recurrent disease.
The limitations of the current study should be taken into 
account. Although data was extracted from a prospectively 
maintained database, HGP determination was performed ret-
rospectively. Also, in 96 potentially eligible patients no HGP 
could be determined, which might have induced selection 
bias. The prognostic value of HGPs and their association 
with salvageability of recurrent disease after first resection 
of CRLM should therefore be validated, preferably in a pro-
spective setting.
In conclusion, the present study confirms that over two-
thirds of patients develop a recurrence after primary resec-
tion of CRLM. Disease recurrence confined to the liver 
is more often seen in patients with dHGP at first CRLM 
resection whereas patients with non-dHGP more frequently 
develop multi-organ recurrence. Importantly, recurrences in 
patients with dHGP at first CRLM resection are more likely 
to be salvageable by local treatment modalities. HGPs deter-
mined at first CRLM resection had no prognostic value after 
salvage therapy for recurrent disease.
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